P O Lim

P O Lim

Auto-generated profile, based on publicly available information

P O Lim

Department of Cardiology, Wales Heart Research Institute, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, Wales, UK

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2001 in Journal Of Hypertension
Verified
Journal Article
Closed access
PLPitt O. Lim
Pitt O. Lim
WYWilliam F. Young
William F. Young
TMThomas M. MacDonald
Thomas M. MacDonald
Use of the aldosterone-to-renin ratio (ARR) has suggested that at least one in 10 hypertensive subjects have primary aldosteronism (PA). There is thus a timely need to review the literature for effective drug therapies and to speculate on other therapeutic options by taking into account recent advances in understanding of the PA disease pathophysiological process. A MEDLINE and EMBASE search of all articles published from the start of the databases until July 1999 and reviews of the bibliographies of textbooks. Primary research articles on the medical treatment of PA with emphasis on diagnosis, treatment option, drug dosage, therapeutic response and adverse drug effect. Study design and quality were assessed. Relevant data on diagnostic methodology, drug usage and response were analysed and compared. A select number of subjects with aldosterone-producing adenoma (APA) can be expected to respond well to surgical treatment. For the majority of PA cases especially subjects with idiopathic hyperaldosteronism (IHA), long-term medical treatment is now safe and feasible although no randomized controlled trials have been carried out to date. The best therapeutic response is obtained by directly antagonizing aldosterone at the receptor level using medium to low dose spironolactone and this response can be predicted by a raised ARR. The response to other potassium-sparing diuretics and calcium channel blockers are modest. IHA responds better than angiotensin II-unresponsive APA to angiotensin converting enzyme inhibitors and this may also be true with angiotensin II receptor blockers. The discovery of the aldosterone synthase gene opens up the possibility for gene therapy. The diagnosis of PA allows appropriate management with resultant blood pressure control in many hypertensive subjects who otherwise have resistant hypertension despite multiple drug therapy.

1 September 2002 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
PLPitt O. Lim
Pitt O. Lim
TMThomas M. Macdonald
Thomas M. Macdonald
CHChristine Holloway
Christine Holloway
EFElaine Friel
Elaine Friel
NANiall H. Anderson
Niall H. Anderson
JCJohn M. C. Connell
John M. C. Connell
The aldosterone-to-renin ratio (ARR) is a marker of aldosterone activity in hypertension. We examined the relationship of the ARR to the distribution of two biallelic polymorphisms at the CYP11B2 gene locus. One polymorphism affects a putative steroidogenic factor-1 binding site (−344 T/C) in the 5′-regulatory region, whereas the other marker reflects replacement of the intron-2 from CYP11B2 with that from the neighboring gene encoding 11β-hydroxylase (CYP11B1; wild-type/conversion). We studied consecutive referrals to the Tayside hypertension clinic in 1998. Because the specificity of ARR (pmol/liter/ng/ml/h) for hyperaldosteronism increases with its threshold, ARRs of at least 750 and 1000 were used. A total of 375 patients were assessed; 86.9% had complete data. There were significant excesses of steroidogenic factor-1 (T) (ARR ≥ 750, 0.62 vs. 0.51, P = 0.014; ARR ≥ 1000, 0.63 vs. 0.51, P = 0.039) and intron-2 (conversion) (ARR ≥ 750, 0.49 vs. 0.41, P = 0.205; ARR ≥ 1000, 0.54 vs. 0.41, P = 0.029) alleles in patients with a raised ARR. The odds ratio for a raised ARR was 2.27 [95% confidence interval, 1.01, 5.09; P < 0.05] comparing patients with a homozygous haplotype for these alleles with those without any such alleles, and this risk increased with age. This study supports the notion that there is a genetic component that regulates aldosterone production and that hyperaldosteronism might develop over time in susceptible individuals.

1 January 2002 in Journal Of Hypertension
Verified
Journal Article
Closed access
PLPitt O. Lim
Pitt O. Lim
ASAllan D. Struthers
Allan D. Struthers
TMThomas M. MacDonald
Thomas M. MacDonald
Use of the aldosterone-to-renin ratio has controversially suggested that approximately 10% of hypertensives have primary aldosteronism, and most of these individuals are thought to have idiopathic hyperaldosteronism. The usual renin-angiotensin system control is intact in these individuals and is similar to that in low renin and essential hypertensives, differing only in the degree of sensitivity. There is recent evidence suggesting that hyperaldosteronism relates to aldosterone synthase genetic polymorphism, and also that increased angiotensin II stimulation of the adrenal glands appears to paradoxically upregulate the receptors increasing angiotensin II sensitivity. Taken together, the possibility arises that, in susceptible hypertensives, hyperaldosteronism could be acquired. Indeed, it is well known that renin-driven renovascular hypertension is associated with the development of hyperaldosteronism. Hypothetically, within the wider hypertensive population, these findings set the scene that angiotensin II adrenal sensitivity increases over time until the secretion of aldosterone becomes "autonomous" and hence "tertiary" aldosteronism in a significant proportion of hypertensives.


1 September 2001 in Journal of Human Hypertension
Verified
Journal Article
Open access
PDF file
PLPo Lim
Po Lim
PDPt Donnan
Pt Donnan
TMTM MacDonald
TM MacDonald
Left ventricular (LV) mass relates positively and continuously to cardiac mortality and thus its regression is a rational therapeutic aim. Whilst the office blood pressure (BP) relates poorly to LV mass, it was unclear whether the 24-h ambulatory BP or the exercise systolic BP (ExSBP) was the stronger correlate of LV structural indices. We studied 49 hypertensive patients with a mean age of 45 (s.d. 12) years with a mean body mass index of 27.1(3.9) kg/m2. The mean (s.d.) of office BP, ambulatory BP and ExSBP measured at the end of the first three stages of Bruce protocol treadmill exercise I, II and III were 161(20)/99(10), 140(13)/89(10), 190(30), 198(30) and 201(33) mm Hg respectively. The LV indices measured echocardiographically were LV septal thickness (IVSd) (1.1(0.2) cm), LV posterior wall thickness (LVPWd) (1.0(0.1) cm) and LV mass indexed to body surface area (LVMI) (123(30) g/m2). Age and gender (male) had the highest correlations with the LV indices. Of the BP measures, the stage II ExSBP’s correlation with the LV indices was consistently higher than all other ExSBP, office systolic BP and 24-h systolic ambulatory BP. In a stepwise multiple regression analysis on IVSd, after adjusting for age and gender, the stage II ExSBP was independently associated with IVSd (β= 0.018 (s.e. 0.008), P = 0.024). When only BP measures were considered as explanatory variables only stage II ExSBP was a significant predictor (P = 0.0001) of IVSd as was the case with LVPWd (P = 0.006) and LVMI (P = 0.0008). Submaximal exercise BP measured at a workload comparable to physical activity encountered in daily life correlated more closely with the left ventricular wall thickness and mass. The exercise BP should perhaps be normalised in hypertension management to optimise regression of LV hypertrophy.

1 July 2002 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
NTN. Tzemos
N. Tzemos
PLP.O. Lim
P.O. Lim
TMT.M. MacDonald
T.M. MacDonald
Blood pressure (BP) during exercise is routinely measured during treadmill testing of individuals with chest pain. An abnormal response, whereby the BP falls or fails to rise during exercise, is universally accepted to be a sign of more severe cardiac ischaemia. Similarly, such responses in patients with hypertrophic cardiomyopathy indicate a high risk for cardiac death, hence exercise BP assessment is now included in the routine work‐up of these patients. The converse, i.e. an exaggerated BP response (ExBPR) during exercise is more controversial, especially when seen in apparently healthy individuals. There are, however, accumulating data to suggest that ExBPR is an early sign of cardiovascular disease. In particular, ExBPR seems to relate to the future development of hypertension, left ventricular hypertrophy (LVH) and is also a potent predictor of future cardiac events. The origin of ExBPR is incompletely understood at present. In this brief review we examine the available literature on the link between cardiovascular disease and ExBPR, and speculate on the nature of this relationship.